Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 10 studies | 25% ± 6% | |
endothelial cell | 9 studies | 19% ± 2% | |
classical monocyte | 6 studies | 27% ± 8% | |
microglial cell | 6 studies | 22% ± 7% | |
dendritic cell | 6 studies | 30% ± 14% | |
macrophage | 6 studies | 22% ± 4% | |
B cell | 5 studies | 18% ± 2% | |
basal cell | 5 studies | 20% ± 4% | |
endothelial cell of lymphatic vessel | 5 studies | 22% ± 4% | |
astrocyte | 5 studies | 25% ± 11% | |
monocyte | 5 studies | 17% ± 1% | |
non-classical monocyte | 4 studies | 25% ± 10% | |
epithelial cell | 4 studies | 33% ± 12% | |
conventional dendritic cell | 3 studies | 22% ± 5% | |
hematopoietic precursor cell | 3 studies | 23% ± 5% | |
myeloid cell | 3 studies | 33% ± 10% | |
ciliated cell | 3 studies | 30% ± 13% | |
retinal cone cell | 3 studies | 20% ± 6% | |
GABAergic neuron | 3 studies | 29% ± 4% | |
glutamatergic neuron | 3 studies | 43% ± 5% | |
naive B cell | 3 studies | 22% ± 4% | |
oligodendrocyte | 3 studies | 26% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3129.62 | 1445 / 1445 | 100% | 38.67 | 183 / 183 |
ovary | 100% | 2042.69 | 180 / 180 | 99% | 21.83 | 426 / 430 |
prostate | 100% | 1854.67 | 245 / 245 | 99% | 18.38 | 497 / 502 |
lung | 100% | 2742.96 | 578 / 578 | 99% | 35.71 | 1142 / 1155 |
uterus | 100% | 2138.99 | 170 / 170 | 99% | 33.50 | 453 / 459 |
breast | 100% | 2713.59 | 459 / 459 | 99% | 36.58 | 1103 / 1118 |
skin | 100% | 4761.21 | 1809 / 1809 | 98% | 40.21 | 464 / 472 |
thymus | 100% | 1993.07 | 651 / 653 | 98% | 34.94 | 594 / 605 |
bladder | 100% | 2264.57 | 21 / 21 | 97% | 24.44 | 490 / 504 |
stomach | 99% | 1442.28 | 357 / 359 | 94% | 15.22 | 270 / 286 |
intestine | 100% | 2240.91 | 965 / 966 | 94% | 15.97 | 495 / 527 |
kidney | 100% | 1444.73 | 89 / 89 | 93% | 27.27 | 838 / 901 |
adrenal gland | 100% | 1277.91 | 258 / 258 | 86% | 11.99 | 197 / 230 |
pancreas | 89% | 733.77 | 291 / 328 | 96% | 21.22 | 171 / 178 |
brain | 89% | 869.86 | 2344 / 2642 | 95% | 16.07 | 673 / 705 |
liver | 95% | 1524.27 | 215 / 226 | 86% | 12.52 | 349 / 406 |
adipose | 100% | 3162.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3184.87 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.71 | 29 / 29 |
spleen | 100% | 4180.11 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 57.83 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.63 | 1 / 1 |
muscle | 98% | 1167.96 | 785 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 2311.39 | 886 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 1530.46 | 819 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 17.15 | 74 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0140110 | Molecular function | transcription regulator activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SERTAD2 |
Protein name | SERTA domain-containing protein 2 (Transcriptional regulator interacting with the PHD-bromodomain 2) (TRIP-Br2) |
Synonyms | TRIPBR2 KIAA0127 |
Description | FUNCTION: Acts at E2F-responsive promoters as coregulator to integrate signals provided by PHD- and/or bromodomain-containing transcription factors. May act as coactivator as well as corepressor of E2F1-TFDP1 and E2F4-TFDP1 complexes on E2F consensus binding sites, which would activate or inhibit E2F-target genes expression. Modulates fat storage by down-regulating the expression of key genes involved in adipocyte lipolysis, thermogenesis and oxidative metabolism. . |
Accessions | Q14140 ENST00000313349.3 |